Masakazu Takeuchi
Overview
Explore the profile of Masakazu Takeuchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
792
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aranishi T, Igarashi A, Hara K, Osumili B, Cai Z, Mizogaki A, et al.
Diabetes Ther
. 2025 Feb;
16(3):447.
PMID: 39918684
No abstract available.
2.
Mimura H, Oura T, Chin R, Takeuchi M, Fujihara K, Sone H
J Diabetes Investig
. 2025 Feb;
PMID: 39891527
Aims/introduction: In the SURPASS J-mono trial, tirzepatide demonstrated significant improvements in bodyweight and several metabolic parameters in Japanese participants with type 2 diabetes. This post hoc analysis evaluated the potential...
3.
Aranishi T, Igarashi A, Hara K, Osumili B, Cai Z, Mizogaki A, et al.
Diabetes Ther
. 2024 Dec;
16(3):431-445.
PMID: 39708085
Introduction: This analysis aimed to evaluate the long-term cost-effectiveness of tirzepatide 5 mg versus dulaglutide 0.75 mg (both administered once weekly) in people not achieving glycemic control on metformin, based...
4.
Fujihara K, Matsubayashi Y, Kitazawa M, Sato T, Takeuchi M, Oura T, et al.
Diabetes Obes Metab
. 2024 Aug;
26(11):5304-5311.
PMID: 39192522
Aim: Normoglycaemia was achieved in a significant proportion of Japanese participants with type 2 diabetes in two phase 3 studies of tirzepatide. This post hoc exploratory analysis aimed to identify...
5.
Morioka T, Takeuchi M, Ozeki A, Emoto M
Diabetes Obes Metab
. 2024 May;
26(8):3167-3175.
PMID: 38715179
Aim: To assess the efficacy and safety of dulaglutide 1.5 mg versus dulaglutide 0.75 mg in Japanese participants with type 2 diabetes (T2D). Materials And Methods: A Phase 3, multicentre,...
6.
Onishi Y, Oura T, Takeuchi M
Diabetes Ther
. 2024 Feb;
15(3):649-661.
PMID: 38310163
Introduction: The presence of metabolic abnormalities in patients with type 2 diabetes (T2D) increases the risk of cardiovascular disease and other comorbidities. This analysis compared the effects of tirzepatide (5,...
7.
Ishii H, Oura T, Takeuchi M
Diabetes Ther
. 2023 Oct;
14(12):2173-2183.
PMID: 37843771
Introduction: Treatment satisfaction in diabetes management is vital to achieving long-term clinical outcomes. This analysis evaluated treatment satisfaction among patients with type 2 diabetes (T2D) after 52 weeks of treatment...
8.
Han W, Wang L, Ohbayashi K, Takeuchi M, OFarrell L, Coskun T, et al.
Diabetes Obes Metab
. 2023 Feb;
25(6):1534-1546.
PMID: 36852745
Aim: To clarify the effects of glucose-dependent insulinotropic polypeptide (GIP) receptor agonists (GIPRAs) on feeding and body weight. Materials And Methods: Acute and subchronic effects of subcutaneous GIPFA-085, a long-acting...
9.
Shirabe S, Yamazaki K, Oishi M, Arai K, Yagi N, Sato M, et al.
J Diabetes Investig
. 2022 Oct;
14(1):75-80.
PMID: 36268571
We assessed the prescription patterns of oral antidiabetic drugs in Japanese patients with type 2 diabetes between 2002 and 2020 using data from the Computerized Diabetes Care database. Among 172,960...
10.
Yabe D, Kawamori D, Seino Y, Oura T, Takeuchi M
Diabetes Obes Metab
. 2022 Oct;
25(2):398-406.
PMID: 36184780
Aim: To evaluate the pharmacodynamic effects of tirzepatide, a novel dual glucagon-like peptide-1 receptor and glucose-dependent insulinotropic polypeptide receptor agonist, compared with dulaglutide in patients with type 2 diabetes. Materials...